Bayer to 'accelerate' five drug candidates and expand on recent launches
This article was originally published in Scrip
Executive Summary
Following the recent launch of five new drugs, Bayer has outlined its plans to keep the momentum going. Five further drug candidates, currently in Phase I and II studies, are being "accelerated" with the aim of getting them into Phase III by 2015.